MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$2,454K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Stock-based compensation expense
Prepaid expenses and other curre...
Others
Negative Cash Flow Breakdown
Net income (loss)
Principal payments on venture de...
Accrued expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net income (loss)
-7,609
57,730
-27,909
-
Non-cash revenue from settlement of customer refund liability
-
53,737
-
-
Amortization of debt discount and issuance costs
33
37
46
97
Amortization of premium on short-term investments
-
0
0
0
Depreciation expense
90
90
91
210
Stock-based compensation expense
1,548
1,469
1,176
2,610
Non-cashlease expense
163
158
158
306
Loss from equity method investment
-
0
0
-
Loss on impairment of equity investment
0
0
0
74
Change in fair value of cvr liability
0
0
0
374
Change in fair value of convertible notes
-
0
0
-
Gain on sale of asset
-
11,737
-
-
Prepaid expenses and other current assets
-302
245
-1,721
-420
Other noncurrent assets
0
0
-570
454
Accounts payable
-226
-94
63
-2,079
Operating lease liability
-168
-157
-155
-300
Accrued expenses and other current liabilities
-476
306
-511
-3,123
Net cash used in operating activities
-6,343
-6,180
-4,230
-23,133
Purchases of property and equipment
-
0
0
0
Proceeds from sale of asset
-
7,000
-
-
Cash acquired in connection with reverse recapitalization
-
0
0
0
Maturities of short-term investments
-
0
0
0
Payment of reverse recapitalization transaction costs
-
0
0
0
Net cash provided by investing activities
0
7,000
0
0
Principal payments on venture debt
-1,563
-1,562
-1,563
-
Proceeds from exercise of common stock options
-
0
0
0
Proceeds from borrowings under loan and security agreement
-
0
0
0
Proceeds from issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs
10,360
0
0
0
Net cash provided by financing activities
8,797
-1,562
-1,563
0
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents
2,454
-742
-5,793
-23,133
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period
48,944
49,686
78,612
-
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period
51,398
48,944
49,686
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock and...
$10,360K
Net cash provided by
financing activities
$8,797K
Canceled cashflow
$1,563K
Net increase
(decrease) in cash, cash...
$2,454K
Canceled cashflow
$6,343K
Principal payments on
venture debt
-$1,563K
Stock-based compensation
expense
$1,548K
Prepaid expenses and
other current assets
-$302K
Non-cashlease expense
$163K
Depreciation expense
$90K
Amortization of debt discount
and issuance costs
$33K
Net cash used in
operating activities
-$6,343K
Canceled cashflow
$2,136K
Net income (loss)
-$7,609K
Accrued expenses and
other current...
-$476K
Accounts payable
-$226K
Operating lease liability
-$168K
Buy us a coffee
Q32 Bio Inc. (QTTB)
Q32 Bio Inc. (QTTB)